Abstract | RATIONALE: AIMS: This study tests the hypothesis that the incidence of hemorrhagic stroke is lower in patients receiving NOACs ( dabigatran, rivaroxaban, apixaban, and edoxaban) than in those receiving warfarin, and this difference reflects the difference in the effects of warfarin and NOACs on the progression of CMBs. DESIGN: We will enroll 200 patients with at least 1 CMB detected by 1.5 T magnetic resonance imaging (T2(∗)-weighted imaging) at baseline and who have received NOACs or warfarin for at least 12 months. Primary end point is the proportion of subjects with an increased number of CMBs at month 12 of treatment with NOACs or warfarin. If the results of this study support the efficacy of NOACs for preventing increase of CMBs, this would be of great interest to domestic and overseas clinicians, in view of the potential therapeutic impact, including that on primary prevention of ischemic stroke.
|
Authors | Shunya Takizawa, Fumiaki Tanaka, Kazutoshi Nishiyama, Yasuhiro Hasegawa, Eiichiro Nagata, Atsushi Mizuma, Sachiko Yutani, Taira Nakayama, Hiroyuki Kobayashi, Noriharu Yanagimachi, Takashi Okazaki, Kazuo Kitagawa, CMB-NOW Study Investigators |
Journal | Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association
(J Stroke Cerebrovasc Dis)
Vol. 24
Issue 9
Pg. 2143-8
(Sep 2015)
ISSN: 1532-8511 [Electronic] United States |
PMID | 26153510
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Observational Study)
|
Copyright | Copyright © 2015 National Stroke Association. Published by Elsevier Inc. All rights reserved. |
Chemical References |
|
Topics |
- Administration, Oral
- Aged
- Aged, 80 and over
- Anticoagulants
(administration & dosage, adverse effects)
- Atrial Fibrillation
(complications, drug therapy)
- Cerebral Hemorrhage
(etiology)
- Female
- Humans
- Longitudinal Studies
- Magnetic Resonance Imaging
- Male
- Pilot Projects
- Stroke
(complications, drug therapy)
- Treatment Outcome
- Warfarin
(adverse effects)
|